Phase 2
N=32
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma · Contiguous Stage II Grade 2 Follicular Lymphoma · Contiguous Stage II Marginal Zone Lymphoma · Cutaneous B-cell Non-Hodgkin Lymphoma · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Bottom Line
View on ClinicalTrials.gov: NCT00244855 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Progression-free Survival — 92; 71; 83; 71 Kaplan-Meier estimated % of patients
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- pharmacological study (Other); rituximab (Biological); dexamethasone (Drug); laboratory biomarker analysis (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Fred Hutchinson Cancer Center
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival |
92; 71; 83; 71 | — |
| SECONDARY Survival |
96; 100; 96; 100; 91; 67 | — |
Summary
This phase II trial studies the side effects and how well giving rituximab and dexamethasone together works in treating patients with low-grade non-Hodgkin lymphoma (NHL). Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with dexamethasone may kill more cancer cells
Eligibility Criteria
Inclusion Criteria
- Patients must have histologically proven CD20+ low grade B cell lymphoma including follicular, marginal zone, monocytoid B cell, and lymphoplasmacytoid lymphoma; patients may be previously untreated or in relapse
- Patients must have measurable disease with clearly defined margins assessed by physical exam with direct measurement (for cutaneous B-cell lymphomas), computed tomography (CT) or magnetic resonance imaging (MRI), defined as >= 20 mm with conventional CT or MRI or >= 10 mm using spiral CT scan
- Absolute neutrophil count >= 1000/mm^3
- Hemoglobin > 7 g/dl
- Platelets >= 100,000/mm^3
- Serum creatinine = = 70 %
- Patient has signed an Institutional Review Board (IRB) approved informed consent form that conforms to federal and institutional guidelines
Exclusion Criteria
- Patient has received rituximab therapy within 6 months of entry into protocol
- Patient has received systemic steroid therapy within one month of entry into protocol
- Patient has Intermediate or High Grade NHL, mantle cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma
- Patient is pregnant or lactating
- Patient is unwilling or unable to practice contraception during treatment and for one year thereafter
- Patient has active central nervous system (CNS) disease
- Patient has human immunodeficiency virus (HIV) disease
- Patient has an active infection requiring antimicrobial therapy
- Patient has significant heart disease, New York Heart Classification III or IV heart disease (III: Marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes fatigue, or dyspnea; IV: Unable to carry on any physical activity without symptoms; symptoms are present even at rest; if any physical activity is undertaken, symptoms are increased)
- Patient requires supplemental oxygen
- Patient has a concomitant malignancy or previous malignancy within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, or in situ cervical or in situ breast cancer
- Patients with active hepatitis B virus (HBV) infection or hepatitis, or with hepatitis C positive serology
Data sourced from ClinicalTrials.gov (NCT00244855). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.